Skip to main content

Table 4 Multivariate analysis for overall survival

From: Comparison of efficacy and safety between simultaneous integrated boost intensity-modulated radiotherapy and conventional intensity-modulated radiotherapy in locally advanced non-small-cell lung cancer: a retrospective study

Characteristics HR 95% CI P value
Age, years (> 70:≤70)   0.279
Gender (female: male)   0.575
KPS (≥80:<80) 0.463 (0.269–0.796) 0.005*
Pathology (ADE:SCC)   0.374
TNM stage (IIIB:IIIA)   0.803
PET staging (yes:no)   0.836
PTV (>535 cc:≤535 cc) 1.627 (1.184–2.237) 0.003*
Concurrent chemoradiotherapy (yes:no) 0.48 (0.348–0.660) < 0.001*
SIB-IMRT (yes:no)   0.504
RT dose (>59Gy: ≤59Gy)   0.595
  1. KPS Karnofsky performance score, ADE Adenocarcinoma, SCC Squamous cell carcinoma, TNM Tumor-node-metastasis, PET Positron emission tomography, PTV Planning target volume, RT Radiotherapy
  2. *p<0.05 was considered significant